2026-03-17 21:08:38
Akari Therapeutics Announces Change in ADS Ratio to Maintain Nasdaq Compliance
Expected Stock impact: Slightly Positive
On March 17, 2026, Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company, announced a significant change in the ratio of its American Depositary Shares (ADSs) to ordinary shares. The company will adjust the ratio from one ADS representing two thousand (2,000) ordinary shares to one ADS representing eighty thousand (80,000) ordinary shares. This change, referred to as the Ratio Change, is set to take effect on or about March 31, 2026. The primary objective of this adjustment is to help Akari maintain compliance with the Nasdaq minimum bid price requirement for continued listing. As a result of the Ratio Change, each ADS holder will need to exchange every forty ADSs for one new ADS. Importantly, this change will not affect the underlying ordinary shares of the company. While the market price per ADS is expected to increase proportionally, Akari has cautioned that there is no assurance that the Ratio Change will successfully meet the Nasdaq's minimum bid price requirement. The company has been proactive in addressing its stock price concerns, and this move is seen as a strategic effort to enhance its market position. Akari Therapeutics continues to focus on developing innovative antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, and its lead candidate, AKTX-101, is designed to target cancer cells effectively. The company is also advancing its pipeline with additional candidates aimed at addressing significant unmet medical needs in oncology. Investors and stakeholders will be closely monitoring the impact of this ratio change on the company's stock performance and overall market perception.
